Medical Condition News

RSS

Combination of BRAF-targeted therapy and immunotherapy shows promise for treatment of melanoma

Combined targeted therapy against the BRAF/MAPK pathway with immunotherapy shows promise as a new therapeutic approach for the treatment of melanoma, according to results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

16 Jun 2010

Newly published research examines association between CKD and CYP24

Cytochroma today announced the publication of new data from studies in a preclinical model indicating that chronic kidney disease is associated with markedly increased expression of the vitamin D catabolic enzyme, CYP24, which contributes to vitamin D insufficiency and resistance to vitamin D therapy. Parallel analysis of kidney biopsies obtained from CKD patients confirmed abnormal CYP24 expression in human disease as well.

16 Jun 2010

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer. Results will provide researchers with a data needed to guide a phase 3 trial.

16 Jun 2010

Normal daily activity best for patients with low-back pain: Study

For much of the 20th century, "rest"— which generally meant a few days to a week in bed — was the standard prescription for acute low-back pain. In recent decades, however, doctors started counseling patients to stay as active as they could.

16 Jun 2010

European Commission grants Orphan Medicinal Product Designation for QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that the European Commission has granted Orphan Medicinal Product Designation for QPI-1002 (also referred to as "I5NP") for the prophylaxis of delayed graft function in kidney transplant patients.

16 Jun 2010

ISB, GIND collaborate on whole-genome sequencing to identify drug targets for Huntington's Disease

The Institute for Systems Biology (ISB) of Seattle, WA, is collaborating with the Gladstone Institute of Neurological Disease (GIND) and its Taube-Koret Center for Huntington's Disease Research to use whole-genome sequencing to identify genes and novel drug targets related to the onset and progression of Huntington's disease (HD). The research team, led by GIND associate director and senior investigator Steven Finkbeiner, MD, PhD, will also use induced pluripotent stem (iPS) cells from patients with HD to screen for drugs that might delay, prevent, or even reverse this devastating condition.

16 Jun 2010

Topical NSAIDs are safe and effective for acute pain: Researchers

Gels, creams and sprays containing painkillers such as ibuprofen, diclofenac, ketoprofen, and piroxicam are safe and effective treatments for local pain, according to Cochrane Researchers. A new systematic review they have conducted shows that topical non-steroidal anti-inflammatory drugs are more effective than placebos for treating short-term pain and have few side effects.

16 Jun 2010

UT Southwestern head and neck cancer surgeons perform area's first transoral robotic surgery

Head and neck cancer surgeons at UT Southwestern Medical Center performed the area's first transoral robotic surgery (TORS), a recently approved minimally invasive no-scar procedure to remove tumors in the throat.

16 Jun 2010

Eating Mediterranean-style diet reduces heart disease risk: Research

A study of twins shows that even with genes that put them at higher risk of cardiovascular disease, eating a Mediterranean-style diet can improve heart function, according to research reported in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

16 Jun 2010

Florida Advisory Council on Radiation Protection endorses ASTRO's Target Safely patient protection plan

Through a unanimous decision, the Florida Advisory Council on Radiation Protection has endorsed Target Safely, the American Society for Radiation Oncology's (ASTRO) patient protection plan.

16 Jun 2010

Course on cancer rehabilitation for nurses and other health professionals

Nurses and other health professionals will soon be able to take a dedicated course on cancer rehabilitation at Swansea University. The master's module in cancer rehabilitation is being launched to help the training of health and social care staff.

16 Jun 2010

NIH awards Geisinger $1.8M grant for study of nuclear ErbB3 protein

A new five-year, $1.8 million National Institutes of Health grant awarded to staff scientist Nikolaos Tapinos, M.D., Ph.D., of Geisinger's Sigfried and Janet Weis Center for Research will be used to study the role of nuclear ErbB3 protein during development of the nervous system and in response to nerve injury.

16 Jun 2010

Cancer overtreatment raises concern; Physicians tend to use new technology even before solid evidence backs it

The Associated Press/Arizona Republic: "It's an unthinkable notion for a generation raised on the message that early cancer detection saves lives, but specialists say more tumors actually are being found too early. That is raising uncomfortable questions about how aggressively to treat early growths -- in some cases, even how aggressively to test -- along with a push for more of the informed-choice programs.

16 Jun 2010

New cancer research centre launched in Edinburgh

Edinburgh today (Wednesday) becomes the next link in a unique chain of Cancer Research UK Centres that are being launched across the UK.

16 Jun 2010

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

QLT Inc. today announced that final results from the Novartis-sponsored Phase IIIb DENALI study were presented on June 8, 2010 during the World Ophthalmology Congress in Berlin. DENALI was a 24-month randomized, double-masked, multicenter trial in patients with subfoveal choroidal neovascularization secondary to wet age-related macular degeneration (all lesion types).

16 Jun 2010

New combination appears to be effective against cancer stem cells in pancreatic cancer

The new cancer medication sorafenib looks promising. Sorafenib is used for advanced liver and kidney cancer and also appears to be effective against cancer stem cells in pancreatic cancer. The team led by Professor Dr. Ingrid Herr, Head of the Department of Molecular Oncosurgery, a group of the Department of Surgery at Heidelberg University Hospital, (Managing Director: Professor Dr. Markus W. B-chler) in cooperation with the German Cancer Research Center, tested the new substance in mice and pancreatic cancer cells.

16 Jun 2010

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the dosing of the first patient in a Phase I/II clinical trial of the doxorubicin conjugate of milatuzumab for the treatment of patients with relapsed multiple myeloma.

16 Jun 2010

ARBs may be linked with increased risk of developing cancer: US scientists

A common class of blood pressure drugs called angiotensin-receptor blockers may be linked with a slightly increased risk of developing cancer, US scientists have found.

16 Jun 2010

LMBRI, Lipopharma Therapeutics collaborate to promote cancer drug development, improve patient outcomes

LMBRI LLC and Lipopharma Therapeutics SL today announced collaboration aimed at transforming cancer drug development and improving patient outcomes. Lipopharma developed new assessment approaches, methods and technologies for developing cancer therapeutics and diagnostics using their proprietary design of structure-based molecules that regulate the structure and functions of the membrane lipids, instead targeting cellular proteins, called "Membrane Lipid-Therapy".

16 Jun 2010

UOHI tests Canada's first in-hospital program to screen and treat patients for diabetes

The University of Ottawa Heart Institute is testing Canada's first in-hospital program to screen and treat patients for diabetes, a growing epidemic in much of the Western world. The program is expected to lead to new ways to identify and cope with one of the most important risk factors for heart disease, particularly in women.

16 Jun 2010

Medical Condition News

Combination of BRAF-targeted therapy and immunotherapy shows promise for treatment of melanoma

Newly published research examines association between CKD and CYP24

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

Normal daily activity best for patients with low-back pain: Study

European Commission grants Orphan Medicinal Product Designation for QPI-1002

ISB, GIND collaborate on whole-genome sequencing to identify drug targets for Huntington's Disease

Topical NSAIDs are safe and effective for acute pain: Researchers

UT Southwestern head and neck cancer surgeons perform area's first transoral robotic surgery

Eating Mediterranean-style diet reduces heart disease risk: Research

Florida Advisory Council on Radiation Protection endorses ASTRO's Target Safely patient protection plan

Course on cancer rehabilitation for nurses and other health professionals

NIH awards Geisinger $1.8M grant for study of nuclear ErbB3 protein

Cancer overtreatment raises concern; Physicians tend to use new technology even before solid evidence backs it

New cancer research centre launched in Edinburgh

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

New combination appears to be effective against cancer stem cells in pancreatic cancer

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

ARBs may be linked with increased risk of developing cancer: US scientists

LMBRI, Lipopharma Therapeutics collaborate to promote cancer drug development, improve patient outcomes

UOHI tests Canada's first in-hospital program to screen and treat patients for diabetes

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Latest News